These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 21970091)

  • 1. Dasatinib: pulmonary arterial hypertension. French data.
    Prescrire Int; 2011 Oct; 20(120):241. PubMed ID: 21970091
    [No Abstract]   [Full Text] [Related]  

  • 2. Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemia.
    Assouline S; Laneuville P; Gambacorti-Passerini C
    N Engl J Med; 2006 Jun; 354(24):2623-4. PubMed ID: 16775249
    [No Abstract]   [Full Text] [Related]  

  • 3. Dasatinib-induced pulmonary hypertension in chronic myelogenous leukaemia.
    Yun S; Anwer F; Vincelette ND
    BMJ Case Rep; 2014 Apr; 2014():. PubMed ID: 24810451
    [No Abstract]   [Full Text] [Related]  

  • 4. Double-edged sword of the new cancer therapeutics.
    Force T
    Circulation; 2012 May; 125(17):2057-8. PubMed ID: 22451582
    [No Abstract]   [Full Text] [Related]  

  • 5. Reversible dasatinib-related pulmonary arterial hypertension diagnosed by noninvasive echocardiography.
    Wang HC; Lee CS; Liu TC
    Kaohsiung J Med Sci; 2015 Mar; 31(3):165-6. PubMed ID: 25744241
    [No Abstract]   [Full Text] [Related]  

  • 6. Reversible pre-capillary pulmonary hypertension due to dasatinib.
    Buchelli Ramirez HL; Álvarez Álvarez CM; Rodríguez Reguero JJ; García Clemente MM; Casan Clarà P
    Respir Care; 2014 May; 59(5):e77-80. PubMed ID: 24149673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Reversible pulmonary hypertension as a consequence of dasatinib treatment in a patient with chronic myeloid leukemia and scleroderma].
    Ryczek R; Góra-Tybor J; Betkier-Lipińska K; Cwetsch A
    Pol Merkur Lekarski; 2013 Jun; 34(204):342-4. PubMed ID: 23882932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia.
    Orlandi EM; Rocca B; Pazzano AS; Ghio S
    Leuk Res; 2012 Jan; 36(1):e4-6. PubMed ID: 21890201
    [No Abstract]   [Full Text] [Related]  

  • 9. Dasatinib in chronic myelogenous leukemia.
    Kathula SK
    N Engl J Med; 2006 Sep; 355(10):1062; author reply 1063-4. PubMed ID: 16957155
    [No Abstract]   [Full Text] [Related]  

  • 10. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia.
    Rasheed W; Flaim B; Seymour JF
    Leuk Res; 2009 Jun; 33(6):861-4. PubMed ID: 18986702
    [No Abstract]   [Full Text] [Related]  

  • 11. Dasatinib-induced pulmonary hypertension in acute lymphoblastic leukemia: case report.
    Taçoy G; Çengel A; Özkurt ZN; Türkoğlu S
    Turk Kardiyol Dern Ars; 2015 Jan; 43(1):78-81. PubMed ID: 25655855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia.
    Dumitrescu D; Seck C; ten Freyhaus H; Gerhardt F; Erdmann E; Rosenkranz S
    Eur Respir J; 2011 Jul; 38(1):218-20. PubMed ID: 21719499
    [No Abstract]   [Full Text] [Related]  

  • 13. Rapid-onset pulmonary arterial hypertension in a patient with acute lymphoblastic leukemia treated with dasatinib.
    Kim JC; Shin SH; Yi HG; Kim SH; Woo SI; Kim DH; Park KS; Kwan J
    Herz; 2013 Dec; 38(8):931-3. PubMed ID: 23430094
    [No Abstract]   [Full Text] [Related]  

  • 14. Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib.
    Oweini H; Otrock ZK; Mahfouz RA; Bazarbachi A
    Arch Gynecol Obstet; 2011 Jan; 283(1):133-4. PubMed ID: 20473616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dasatinib-induced gastric antral vascular ectasia in a patient with acute lymphoblastic leukaemia.
    Ohta S; Najima Y; Imamura J
    Br J Haematol; 2015 Jun; 169(5):612. PubMed ID: 25855138
    [No Abstract]   [Full Text] [Related]  

  • 16. Tyrosine kinase inhibitors in pulmonary arterial hypertension: a double-edge sword?
    Godinas L; Guignabert C; Seferian A; Perros F; Bergot E; Sibille Y; Humbert M; Montani D
    Semin Respir Crit Care Med; 2013 Oct; 34(5):714-24. PubMed ID: 24037637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progressive arterial occlusive disease (PAOD) and pulmonary arterial hypertension (PAH) as new adverse events of second generation TKIs in CML treatment: who's afraid of the big bad wolf?
    Breccia M; Efficace F; Alimena G
    Leuk Res; 2012 Jul; 36(7):813-4. PubMed ID: 22483067
    [No Abstract]   [Full Text] [Related]  

  • 18. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
    Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
    N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dasatinib, a multikinase inhibitor: therapy, safety, and appropriate management of adverse events.
    Shayani S
    Ther Drug Monit; 2010 Dec; 32(6):680-7. PubMed ID: 20864900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.